Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2021

View Archived Issues

Noncanonical NLRC4 inflammasome mechanism offers new targets for sterile inflammatory disorders

SOCS1 is a major intracellular negative checkpoint of adoptive T-cell responses

Human mAbs prove a safe alternative to tetanus Ig for tetanus prevention and treatment in mice

Novel pleuromutilin derivatives with promising anti-MRSA activity

LAIR-1-targeting antibody NC-525 potentially effective against AML

Biomimetic synthesis of compounds from naturally abundant arglabin

SL-010110 inhibits gluconeogenesis and improves glucose homeostasis in diabetic mice

Topspin Therapeutics patents TMPRSS2 inhibitors

Autobahn Therapeutics divulges new thyromimetic compounds

Gilead Sciences identifies new LPAR1 antagonists

KSQ Therapeutics synthesizes USP1 inhibitors

Yumanity Therapeutics discloses PIKfyve inhibitors

Broader look reveals more contributions to chemotherapy damage

BiondVax signs agreements with Max Planck and UMG for COVID-19 NanoAbs

Novel aztreonam conjugates with promising activity against Gram-negative bacteria

Researchers present exosome-mediated system delivery of therapeutic cargo for HIV-1 repression

Claritas to develop R-107 for persistent pulmonary hypertension of the newborn

LogicBio nominates development candidate for treatment of hereditary tyrosinemia type 1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...